TPST (Tempest Therapeutics) 3-1 Month Momentum %: -38.05% (As of Jul. 11, 2026)


TPST Tempest Therapeutics Inc TPST
32 GF Score
Price $0.97
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics 3-1 Month Momentum %?

Tempest Therapeutics TPST -0.18% 32 3-1 Month Momentum % is -38.05% as of Jul. 11, 2026. GuruFocus rates TPST with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,385 Biotechnology companies, Tempest Therapeutics ranks worse than 67.29% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-11), Tempest Therapeutics's 3-1 Month Momentum % is -38.05%.

The industry rank for Tempest Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

TPST's 3-1 Month Momentum % is ranked worse than
67.29% of 1385 companies
in the Biotechnology industry
Industry Median: -10.98 vs TPST: -38.05

Tempest Therapeutics  (NAS:TPST) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Tempest Therapeutics 3-1 Month Momentum % Related Terms

TPST vs HOWL, INTI, GTBP: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Tempest Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's 3-1 Month Momentum % falls into.


TPST
32GF Score
Tempest Therapeutics Inc TPST
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics  (NAS:TPST) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -38.05% mean?
Tempest Therapeutics (TPST) has a 3-1 Month Momentum % of -38.05% as of Jul. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tempest Therapeutics and its competitors. According to the industry distribution chart, Tempest Therapeutics ranks #932 out of 1385 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Tempest Therapeutics' 3-1 Month Momentum % too high?
Tempest Therapeutics' current 3-1 Month Momentum % is -38.05%. Based on the distribution chart, Tempest Therapeutics ranks #932 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tempest Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' 3-1 Month Momentum % compare to HOWL and INTI?
According to the Biotechnology industry distribution chart, Tempest Therapeutics ranks #932 out of 1385 companies for 3-1 Month Momentum %. This places Tempest Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current 3-1 Month Momentum % is -38.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current 3-1 Month Momentum % of -38.05%. The current 3-1 Month Momentum % is -38.05%. Tempest Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current 3-1 Month Momentum % is -38.05% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
32GF Score

Get the complete analysis for TPST

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price